Loading…
Operates in Pharma — Distribution. Per the activity note to the FY2024 annual report, the company trades pharmaceutical medicines at retail and wholesale.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 13.2% | 19.9% | 25.9% | 32.9% | 38.8% | 40.5% | 46.4% |
| EBITDA Margin | -6.9% | 2.0% | -2.0% | 5.7% | 2.0% | 3.4% | 6.6% |
| EBITDAR | -888 | 337 | -203 | 1,289 | 500 | 808 | 1,609 |
| EBITDAR Margin | -6.2% | 2.7% | -1.2% | 6.4% | 2.3% | 3.5% | 6.7% |
| EBIT Margin | -6.9% | 2.0% | -2.0% | 5.7% | 2.0% | 3.4% | 6.6% |
| Net Profit Margin | -6.9% | 1.3% | -2.1% | 5.7% | 1.4% | 2.9% | 6.1% |
| Operating Expense % of Sales | 20.1% | 18.0% | 27.9% | 27.2% | 36.9% | 37.2% | 39.8% |
| Returns | |||||||
| Return on Assets (ROA) | -14.4% | 2.1% | -5.3% | 17.6% | 4.4% | 7.3% | 15.8% |
| Return on Equity (ROE) | -18.2% | 2.9% | -6.7% | 30.0% | 5.4% | 10.7% | 19.3% |
| ROIC [EBIT / Invested Capital] | -19.3% | 4.2% | -5.9% | 26.0% | 6.7% | 10.0% | 20.9% |
| Leverage & debt balances | |||||||
| Debt-to-Assets | 0.0% | 9.7% | 7.0% | 14.5% | 15.2% | 20.0% | 11.0% |
| Debt-to-Equity | 0.00x | 0.13x | 0.09x | 0.25x | 0.19x | 0.29x | 0.13x |
| Debt-to-EBITDA | N/A | 3.07x | N/A | 0.82x | 2.42x | 2.32x | 0.64x |
| Equity-to-Assets | 79.2% | 72.0% | 79.6% | 58.7% | 80.8% | 67.7% | 82.1% |
| Net Debt | -317 | 235 | 198 | 581 | 840 | 1,653 | -42 |
| Cash & Equivalents | 317 | 525 | 263 | 359 | 187 | 141 | 1,050 |
| Total Debt | N/A | 759 | 462 | 940 | 1,026 | 1,794 | 1,008 |
| Liquidity & working capital | |||||||
| Current Ratio | 3.46x | 3.48x | 4.37x | 1.77x | 26.22x | 2.55x | 4.21x |
| Quick Ratio | 3.46x | 0.83x | 1.45x | 1.77x | 26.22x | 2.55x | 4.21x |
| Cash Ratio | 0.31x | 0.42x | 0.30x | 0.21x | 1.25x | 0.09x | 1.41x |
| Total Current Assets | 3,579 | 4,365 | 3,891 | 3,065 | 3,900 | 3,914 | 3,129 |
| Total Current Liabilities | 1,034 | 1,253 | 891 | 1,730 | 149 | 1,536 | 743 |
| Inventory | N/A | 3,321 | 2,602 | N/A | N/A | N/A | N/A |
| Trade Receivables | 2,749 | 3,573 | 3,389 | 1,695 | 1,108 | 3,084 | 2,827 |
| Trade Payables | 1,034 | 1,245 | 891 | 1,634 | 144 | 969 | 639 |
| Net Working Capital | 2,545 | 3,112 | 3,001 | 1,335 | 3,751 | 2,377 | 2,387 |
| Net Working Capital % of Revenue | 17.8% | 24.6% | 18.2% | 6.6% | 17.4% | 10.4% | 10.0% |
| Trade Working Capital | 1,715 | 5,649 | 5,100 | 61 | 965 | 2,114 | 2,188 |
| Trade Working Capital % of Revenue | 12.0% | 44.6% | 30.9% | 0.3% | 4.5% | 9.3% | 9.2% |
| Change in Trade Working Capital | N/A | 3,933 | -549 | -5,039 | 904 | 1,150 | 73 |
| Turnover & efficiency | |||||||
| Inventory Turnover | N/A | 3.05x | 4.70x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | 119.5 | 77.6 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 5.21x | 3.54x | 4.88x | 11.87x | 19.43x | 7.40x | 8.45x |
| Days Sales Outstanding (DSO) | 70.1 | 103.0 | 74.9 | 30.8 | 18.8 | 49.3 | 43.2 |
| Payables Turnover | 12.02x | 8.14x | 13.74x | 8.27x | 91.66x | 13.99x | 20.01x |
| Days Payable Outstanding (DPO) | 30.4 | 44.8 | 26.6 | 44.2 | 4.0 | 26.1 | 18.2 |
| Cash Conversion Cycle | 39.7 days | 177.7 days | 125.9 days | -13.4 days | 14.8 days | 23.3 days | 25.0 days |
| Asset Turnover | 2.07x | 1.62x | 2.49x | 3.11x | 3.20x | 2.54x | 2.60x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | -9 | 208 | -261 | 95 | -142 | 188 | N/A |
| Free Cash Flow (OCF − Capex proxy) | -9 | 208 | -261 | 95 | -142 | 188 | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | 83.9% | N/A | 8.4% | -33.5% | 24.3% | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →